1,0
9 apr 2021
Dipendente attuale, più di un anno
El Segundo, CA
Consiglia
Gradimento del CEO
Pronostico commerciale
Vantaggi
Great Pay, Decent benefits and ambitious goals.
Svantaggi
Not a Quality based company since merging with NantKwest, cutting corners in GMP and GDP is incentivized by managers. No defined roles for individuals, titles are meaningless since people tasks don't reflect titles. No accountability of departments and most middle management positions held by individuals with little or no science background. Not really a data/fact based company now since NantKwest merger and very little transparency. Poor communication, Managers are never present and have a "no email" policy, which is suspicious. I would not want to be here during an FDA audit.